Cure My Disease

Don't miss your cure!

 Log in / Sign up

Donor cells join forces with antibody to fight tough lymphomas

NCT ID NCT04848064

Recruiting now Disease control Sponsor: John Reneau Source: ClinicalTrials.gov ↗

First seen Feb 12, 2026 · Last updated May 14, 2026 · Updated 15 times

Summary

This early-phase trial tests a combination of donated natural killer (NK) immune cells and a drug called mogamulizumab for people with certain T-cell lymphomas that have returned or not responded to prior treatment. The study aims to find the safest dose and see if the combination can shrink tumors. About 12 adults with relapsed or refractory cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA REFRACTORY ADULT T-CELL LEUKEMIA/LYMPHOMA REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA